stockrowKymera Therapeutics, Inc.
KYMR Healthcare Biotechnology
Kymera Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $39.2 million, down 16.7% from fiscal 2024.
- Revenue
- +466.4%
- EPS
- −40.3%
- Free cash flow
- −186.6%
- Total debt
- −66.6%
Quarter to September 2026, against a year earlier
Follow KYMR
Alert me
Kymera Therapeutics, Inc. (KYMR) EBITDA
Kymera Therapeutics, Inc.'s EBITDA for fiscal 2025 was −$350.0M, compared with −$268.2M in fiscal 2024. Over the twelve months to 30 September 2026 it was −$405.5M. Over the past ten years it has ranged from −$350.0M (fiscal 2025) to −$21.2M (fiscal 2018) — the current reading is the lowest in ten years. EBITDA has fallen for 7 consecutive fiscal years. Kymera Therapeutics, Inc. ranks 564th of 594 Biotechnology companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | −$350.0M | — |
| FY2024 | −$268.2M | — |
| FY2023 | −$167.2M | — |
| FY2022 | −$157.4M | — |
| FY2021 | −$92.3M | — |
| FY2020 | −$43.0M | — |
| FY2019 | −$41.4M | — |
| FY2018 | −$21.2M | — |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Sep 2026 | −$146.8M | — |
| Jun 2026 | −$75.9M | — |
| Mar 2026 | −$84.9M | — |
| Dec 2025 | −$97.9M | — |
| 24 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| BMRN BioMarin Pharmaceutical Inc. compare | $374.0M |
| TECH Bio-Techne Corp compare | $349.2M |
| CAI Caris Life Sciences,�Inc. compare | $180.0M |
| TGTX TG Therapeutics, Inc. compare | $136.0M |
| TWST Twist Bioscience Corporation compare | −$119.6M |
| IBRX ImmunityBio, Inc. compare | −$235.2M |
| KYMR Kymera Therapeutics, Inc. | −$405.5M |
| SMMT Summit Therapeutics PLC compare | −$872.8M |
| PCVX Vaxcyte, Inc. compare | −$1.1B |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on KYMR
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement